Table 1.

Selected Participant Characteristics by Treatment

Variables	All patients (n = 71)	Conventional treatment (n = 38)	Burosumab treatment (n = 33)	Comparison between conventional treatment and burosumab (p)
Sex, n (%)
Male	30 (42.3)	16 (42.1)	14 (42.4)
Female	41 (57.7)	22 (57.9)	19 (57.6)	0.98
Age at XLH treatment onset (years), mean ± SD	5.45 ± 4.34	2.92 ± 3.0	8.36 ± 3.81	0.00001
XLH treatment duration (months), mean ± SD	70.5 ± 49.2	97.9 ± 46.9	38.9 ± 29.0	0.0001
Alkaline phosphatase level (IU/L), mean ± SD	364.4 ± 138.9	385.8 ± 147.7	339.8 ± 125.7	0.17
Age at dental follow‐up onset (years), mean ± SD	7.86 ± 3.76	6.58 ± 3.33	9.33 ± 3.72	0.004
Dental follow‐up duration (months), mean ± SD	41.5 ± 27.5	53.9 ± 31.9	27.2 ± 9.6	0.0009
Number of dental abscess per month of dental follow‐up (n/month), mean ± SD	0.03 ± 0.04	0.04 ± 0.05	0.01 ± 0.03	0.04
Number of maxillofacial cellulitis per month of dental follow‐up (n/month), mean ± SD	0.004 ± 0.02	0.007 ± 0.02	0.002 ± 0.008	0.23
Dental caries during dental follow‐up, n (%)	13 (18.3)	7 (18.4)	6 (18.2)	0.98